全文获取类型
收费全文 | 5542篇 |
免费 | 309篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 138篇 |
妇产科学 | 162篇 |
基础医学 | 702篇 |
口腔科学 | 146篇 |
临床医学 | 374篇 |
内科学 | 1438篇 |
皮肤病学 | 110篇 |
神经病学 | 516篇 |
特种医学 | 142篇 |
外科学 | 921篇 |
综合类 | 31篇 |
预防医学 | 321篇 |
眼科学 | 81篇 |
药学 | 235篇 |
中国医学 | 15篇 |
肿瘤学 | 476篇 |
出版年
2023年 | 49篇 |
2022年 | 110篇 |
2021年 | 285篇 |
2020年 | 121篇 |
2019年 | 217篇 |
2018年 | 229篇 |
2017年 | 165篇 |
2016年 | 138篇 |
2015年 | 144篇 |
2014年 | 226篇 |
2013年 | 292篇 |
2012年 | 460篇 |
2011年 | 522篇 |
2010年 | 263篇 |
2009年 | 239篇 |
2008年 | 357篇 |
2007年 | 361篇 |
2006年 | 347篇 |
2005年 | 327篇 |
2004年 | 256篇 |
2003年 | 239篇 |
2002年 | 208篇 |
2001年 | 30篇 |
2000年 | 31篇 |
1999年 | 40篇 |
1998年 | 43篇 |
1997年 | 29篇 |
1996年 | 15篇 |
1995年 | 20篇 |
1994年 | 14篇 |
1993年 | 18篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1981年 | 9篇 |
1980年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1947年 | 1篇 |
1944年 | 1篇 |
1942年 | 1篇 |
1936年 | 1篇 |
1920年 | 1篇 |
排序方式: 共有5885条查询结果,搜索用时 109 毫秒
101.
Susanne Halken Desiree Larenas‐Linnemann Graham Roberts Moises A. Calderón Elisabeth Angier Oliver Pfaar Dermot Ryan Ioana Agache Ignacio J. Ansotegui Stefania Arasi George Du Toit Montserrat Fernandez‐Rivas Roy Geerth van Wijk Marek Jutel Jörg Kleine‐Tebbe Susanne Lau Paolo M. Matricardi Giovanni B. Pajno Nikolaos G. Papadopoulos Martin Penagos Alexandra F. Santos Gunter J. Sturm Frans Timmermans R. van Ree Eva‐Maria Varga Ulrich Wahn Maria Kristiansen Sangeeta Dhami Aziz Sheikh Antonella Muraro 《Pediatric allergy and immunology》2017,28(8):728-745
Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease‐modifying treatment for IgE‐mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence‐based recommendations for AIT for the prevention of (i) development of allergic comorbidities in those with established allergic diseases, (ii) development of first allergic condition, and (iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multidisciplinary expert working group, a systematic review of the underpinning evidence, and external peer‐review of draft recommendations. Our key recommendation is that a 3‐year course of subcutaneous or sublingual AIT can be recommended for children and adolescents with moderate‐to‐severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to 2 years post‐AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than 2 years post‐AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease, or for the prevention of allergic comorbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease‐modifying treatment exists but there is an urgent need for more high‐quality clinical trials. 相似文献
102.
103.
104.
105.
106.
107.
AndrewJ. Stott Michel C. Maillard Vahri Beaumont David Allcock Omar Aziz Alexander H. Borchers Wesley Blackaby Perla Breccia Gillian Creighton-Gutteridge Alan F. Haughan Rebecca E. Jarvis Christopher A. Luckhurst Kim L. Matthews George McAllister Scott Pollack Elizabeth Saville-Stones Amanda J. Van de Poël Huw D. Vater Julie Vann Rachel Williams Dawn Yates Ignacio Muoz-Sanjun Celia Dominguez 《ACS medicinal chemistry letters》2021,12(3):380
Using an iterative structure–activity relationship driven approach, we identified a CNS-penetrant 5-(trifluoromethyl)-1,2,4-oxadiazole (TFMO, 12) with a pharmacokinetic profile suitable for probing class IIa histone deacetylase (HDAC) inhibition in vivo. Given the lack of understanding of endogenous class IIa HDAC substrates, we developed a surrogate readout to measure compound effects in vivo, by exploiting the >100-fold selectivity compound 12 exhibits over class I/IIb HDACs. We achieved adequate brain exposure with compound 12 in mice to estimate a class I/IIb deacetylation EC50, using class I substrate H4K12 acetylation and global acetylation levels as a pharmacodynamic readout. We observed excellent correlation between the compound 12 in vivo pharmacodynamic response and in vitro class I/IIb cellular activity. Applying the same relationship to class IIa HDAC inhibition, we estimated the compound 12 dose required to inhibit class IIa HDAC activity, for use in preclinical models of Huntington’s disease. 相似文献
108.
109.
110.
Carlos A. Jiménez Ruiz Daniel Buljubasich Juan Antonio Riesco Miranda Agustín Acuña Izcaray José Ignacio de Granda Orive José Miguel Chatkin Gustavo Zabert Alfredo Guerreros Benavides Nelson Paez Espinel Valeri Noé Efraín Sánchez-Angarita Ingrid Núñez-Sánchez Raúl H. Sansores Alejandro Casas Andrés Palomar Lever Inmaculada Alfageme Michavila 《Archivos de bronconeumología》2017,53(11):622-628
The ALAT and SEPAR Treatment and Control of Smoking Groups have collaborated in the preparation of this document which attempts to answer, by way of PICO methodology, different questions on health interventions for helping COPD patients to stop smoking.The main recommendations are: (i) moderate-quality evidence and strong recommendation for performing spirometry in COPD patients and in smokers with a high risk of developing the disease, as a motivational tool (particularly for showing evidence of lung age), a diagnostic tool, and for active case-finding; (ii) high-quality evidence and strong recommendation for using intensive dedicated behavioral counselling and drug treatment for helping COPD patients to stop smoking; (iii) high-quality evidence and strong recommendation for initiating interventions for helping COPD patients to stop smoking during hospitalization with improvement when the intervention is prolonged after discharge, and (iv) high-quality evidence and strong recommendation for funding treatment of smoking in COPD patients, in view of the impact on health and health economics. 相似文献